Nivolumab Associated With Durable Long-term Responses in Lung Cancer

Share this content:
Immune checkpoint inhibition with nivolumab is associated with durable clinical responses and a 16% 5-year survival rate among heavily pretreated patients with advanced NSCLC.
Immune checkpoint inhibition with nivolumab is associated with durable clinical responses and a 16% 5-year survival rate among heavily pretreated patients with advanced NSCLC.

Immune checkpoint inhibition with nivolumab is associated with durable clinical responses and a 16% 5-year survival rate among heavily pretreated patients with advanced non-small cell lung cancer (NSCLC), reported authors of an analysis of data from a phase 1 clinical trial (ClinicalTrials.gov Identifier: NCT00730639) presented at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C.1

“This is the first report of the long-term survival rate in patients with metastatic NSCLC treated with an immune checkpoint inhibitor,” reported study coauthor Julie Brahmer, MD, an associate professor of oncology at the Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins University in Baltimore, Maryland, in a press release. “Our study results show that for a small subset of patients, immunotherapy can work for a very long time.”

The cohort saw a 5-year survival rate more than triple that for patients undergoing standard-of-care treatment noted in the National Cancer Institute (NCI)'s Surveillance, Epidemiology, and End Results program (SEER) database. SEER rates for patients with advanced NSCLC are 4.9%, compared with 15% and 16% among study participants with non-squamous and squamous NSCSLC.

The authors compared study participants' survival rates with historical SEER data because the trial had not been randomized.

Sixteen study participants survived at least 5 years. Twelve saw partial responses (PR), 2 had stable disease (SD) and 2 experienced disease progression as best response.

Eight completed 2 years of treatment without adverse events, but treatment was discontinued for 4 patients because of side effects.

RELATED: FDA Approves Osimertinib for EGFR T790M Mutation-positive NSCLC

Data on study participants' tumor PD-L1 status were incomplete, but among those for which they were available, PD-L1 status was not clearly associated with survival, Dr Brahmer noted.

Reference

  1. Shorter sleep duration is associated with increased risk of fatal prostate cancer in younger men [news release]. Washington, DC: American Association for Cancer Research; April 3, 2017. http://mb.cision.com/Public/3069/2224884/ a4bac94ff66eedce.pdf. Accessed April 4, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters